Lupin buys 3 anti-diabetes trademarks from Boehringer Ingelheim
Mumbai: Global pharma major Lupin Limited has announced the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET and AJADUO from BoehringerIngelheim International GmbH, to strengthen its diabetes portfolio in the country.
As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO and GIBTULIO MET since 2016, and AJADUO since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India.
GIBTULIO (empagliflozin), GIBTULIO MET (empagliflozin + metformin) and AJADUO (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations).
These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.
An estimated 80 million people above the age of 18 years have diabetes in India, in addition to 25 million that are pre-diabetic. Awareness of diabetes is low with more than 50% of people unaware of their diabetic status, leading to multiple health complications, if not detected and treated early. Adults with diabetes have an increased risk of heart attack and stroke.
“Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India,” said Nilesh Gupta, Managing Director, Lupin. Commenting on the acquisition, Rajeev Sibal, President – India Region Formulations, Lupin said, “The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.